Edition:
United States

Express Scripts Holding Co (ESRX.OQ)

ESRX.OQ on NASDAQ Stock Exchange Global Select Market

75.19USD
23 Apr 2018
Change (% chg)

$1.70 (+2.31%)
Prev Close
$73.49
Open
$73.75
Day's High
$75.51
Day's Low
$72.91
Volume
1,138,502
Avg. Vol
1,649,836
52-wk High
$85.05
52-wk Low
$55.80

Latest Key Developments (Source: Significant Developments)

Express Scripts Says 2018 Annual Bonus Plan To Be Funded At 200% With No Proration If Cigna Deal Closes In 2018
Monday, 19 Mar 2018 05:45pm EDT 

March 19 (Reuters) - Express Scripts Holding Co :EXPRESS SCRIPTS HOLDING SAYS IF CIGNA DEAL CLOSES IN 2018, 2018 ANNUAL BONUS PLAN TO BE FUNDED AT 200% WITH NO PRORATION - SEC FILING.EXPRESS SCRIPTS-IF CIGNA DEAL NOT CLOSED IN 2018, FINANCIAL TARGETS SET AT START OF YEAR TO BE USED TO DETERMINE FUNDING OF 2018 BONUS FOR Q1 2019 PAYOUT.  Full Article

Express Scripts Says If Cigna Merger Terminated Co To Pay Cigna $1.6 Bln
Friday, 9 Mar 2018 05:44pm EST 

March 9 (Reuters) - Express Scripts Holding Co : :EXPRESS SCRIPTS HOLDING SAYS IF MERGER AGREEMENT WITH CIGNA TERMINATED UNDER CERTAIN CONDITIONS, THEN CO MUST PAY CIGNA FEE OF $1.6 BILLION - SEC FILING.EXPRESS SCRIPTS HOLDING SAYS CIGNA HAS RECIPROCAL OBLIGATIONS TO PAY $1.6 BILLION TERMINATION FEE TO CO IF MERGER DEAL TERMINATED UNDER CERTAIN CONDITIONS.EXPRESS SCRIPTS - IF MERGER DEAL TERMINATED BY EITHER CO, CIGNA UNDER FURTHER CERTAIN CONDITIONS, CIGNA MAY BE REQUIRED TO PAY CO REVERSE FEE OF $2.1 BILLION.  Full Article

Express Scripts CEO Does Not Expect To Lose Health Insurer Customers
Thursday, 8 Mar 2018 09:00am EST 

March 8 (Reuters) - Express Scripts Holding Co ::EXPRESS SCRIPTS CEO DOES NOT EXPECT TO LOSE HEALTH INSURER CUSTOMERS AS A RESULT OF BEING BOUGHT BY INSURER CIGNA.  Full Article

Cigna Expects 2021 Earnings Of $20 To $21 Per Share
Thursday, 8 Mar 2018 08:30am EST 

March 8 (Reuters) - Express Scripts Holding Co ::CIGNA EXPECTS 2021 EARNINGS OF $20 TO $21 PER SHARE, UP FROM TARGET OF $18 PER SHARE, DUE TO EXPRESS SCRIPTS DEAL.  Full Article

Cigna Says Deal To Provide Greater Than About $600 Mln In Retained Synergies
Thursday, 8 Mar 2018 07:51am EST 

March 8 (Reuters) - Cigna Corp ::CIGNA SAYS DEAL TO PROVIDE GREATER THAN ABOUT $600 MILLION IN RETAINED SYNERGIES - PRESENTATION.  Full Article

Express Scripts Reports Q4 Adjusted Earnings Per Share $2.16
Tuesday, 27 Feb 2018 04:01pm EST 

Feb 27 (Reuters) - Express Scripts Holding Co ::EXPRESS SCRIPTS ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $2.16.Q4 GAAP EARNINGS PER SHARE $4.10.REAFFIRMS FY 2018 ADJUSTED EARNINGS PER SHARE VIEW $9.27 TO $9.47.SEES Q1 2018 ADJUSTED EARNINGS PER SHARE $1.73 TO $1.78.QTRLY REVENUE $25,378.8 MILLION VERSUS $24,863.3 MILLION REPORTED LAST YEAR.Q4 REVENUE VIEW $25.10 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $2.09 -- THOMSON REUTERS I/B/E/S.‍​EXPECTS TOTAL ADJUSTED CLAIMS FOR Q1 TO BE IN THE RANGE OF 335 MILLION TO 345 MILLION.QTRLY ADJUSTED CLAIMS OF 355.8 MILLION, FLAT FROM 2016.Q1 EARNINGS PER SHARE VIEW $1.74 -- THOMSON REUTERS I/B/E/S.  Full Article

Express Scripts And Walgreens Boots Alliance Expand Group Purchasing Efforts To Include Specialty Brand Medications
Tuesday, 20 Feb 2018 04:01pm EST 

Feb 20 (Reuters) - Express Scripts Holding Co ::EXPRESS SCRIPTS AND WALGREENS BOOTS ALLIANCE EXPAND GROUP PURCHASING EFFORTS TO INCLUDE SPECIALTY BRAND MEDICATIONS.WALGREENS BOOTS ALLIANCE - CO'S AND EXPRESS SCRIPTS' WORK WILL BE SUPPORTED BY VALOREMRX SPECIALTY SOLUTIONS LLC.  Full Article

Express Scripts Canada Awarded Health Canada Contract
Thursday, 1 Feb 2018 07:30am EST 

Feb 1 (Reuters) - Express Scripts Inc [RIC:RIC:EXPR.UL]::EXPRESS SCRIPTS CANADA AWARDED HEALTH CANADA CONTRACT.EXPRESS SCRIPTS CANADA SAYS FIVE-YEAR CONTRACT INCLUDES RENEWAL OPTIONS THAT CAN TOTAL UP TO 11 YEARS.  Full Article

Express Scripts Holding Sees FY 2017 ADJ SHR $7.00 To $7.08
Thursday, 14 Dec 2017 07:30am EST 

Dec 14 (Reuters) - Express Scripts Holding Co ::EXPRESS SCRIPTS HOLDING COMPANY UPDATES 2017 FULL-YEAR GUIDANCE AND ANNOUNCES 2018 FINANCIAL GUIDANCE.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $7.67 TO $7.87.SEES FY 2017 ADJUSTED EARNINGS PER SHARE $7.00 TO $7.08.EXPECTS 2017 FULL-YEAR TOTAL ADJUSTED CLAIMS FOR ITS CORE BUSINESS TO BE IN RANGE OF 1,158 MILLION TO 1,172 MILLION.NARROWED PREVIOUSLY ISSUED CONSOLIDATED 2017 ADJUSTED EBITDA GUIDANCE TO A RANGE OF $7,370 MILLION TO $7,450 MILLION.ESTIMATE THAT EVICORE ACQUISITION WILL GENERATE EBITDA OF $265 MILLION TO $285 MILLION IN 2018.EVICORE ACQUISITION AND SALE OF UNITED BIOSOURCE ARE EXPECTED TO BE COMPLETED IN DECEMBER 2017.ENTERPRISE VALUE INITIATIVE ESTIMATED TO COST ABOUT $600-$650 MILLION & TO DELIVER CUMULATIVE SAVINGS OF NEARLY $1.2 BILLION BY 2021.FY2017 EARNINGS PER SHARE VIEW $7.01 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $7.65 -- THOMSON REUTERS I/B/E/S.SEES CORE ESTIMATED REVENUE FOR 2018 OF $80,500 MILLION TO $83,000 MILLION.SEES CONSOLIDATED ESTIMATED REVENUE FOR 2018 OF $99,000 MILLION TO $102,000 MILLION.FY2018 REVENUE VIEW $101.29 BILLION -- THOMSON REUTERS I/B/E/S.COMPANY EXPECTS CORE 2017 FULL-YEAR ADJUSTED EBITDA GUIDANCE IN RANGE OF $4,910 MILLION TO $4,970 MILLION.SEES CORE ESTIMATED TOTAL ADJUSTED CLAIMS FOR 2018 OF 1,125 MILLION TO 1,165 MILLION.SEES CONSOLIDATED ESTIMATED TOTAL ADJUSTED CLAIMS FOR 2018 OF 1,345 MILLION TO 1,395 MILLION.  Full Article

Avista Capital Partners To Acquire Express Scripts' Subsidiary United Biosource
Monday, 27 Nov 2017 09:15am EST 

Nov 27 (Reuters) - Express Scripts Holding Co ::AVISTA CAPITAL PARTNERS TO ACQUIRE EXPRESS SCRIPTS' SUBSIDIARY UNITED BIOSOURCE.AVISTA CAPITAL PARTNERS TO ACQUIRE EXPRESS SCRIPTS' SUBSIDIARY UNITED BIOSOURCE.EXPRESS SCRIPTS HOLDING CO - ‍AVISTA SIGNED DEFINITIVE AGREEMENT TO ACQUIRE UNITED BIOSOURCE, A SUBSIDIARY OF CO.  Full Article

Photo

Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

LOS ANGELES The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.